PharmaCielo (TSXV:PCLO) Debt-to-Revenue : 11.93 (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is PharmaCielo Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

PharmaCielo's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was C$1.14 Mil. PharmaCielo's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was C$15.66 Mil. PharmaCielo's annualized Revenue for the quarter that ended in Sep. 2023 was C$1.41 Mil. PharmaCielo's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 was 11.93.

PharmaCielo Debt-to-Revenue Historical Data

The historical data trend for PharmaCielo's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaCielo Debt-to-Revenue Chart

PharmaCielo Annual Data

Trend

Aug17

Aug18

Dec19

Dec20

Dec21

Dec22

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

2.00

1.69

4.33

2.37

PharmaCielo Quarterly Data
	Nov18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Revenue	Get a 7-Day Free Trial															6.12	2.08	4.54	24.02	11.93

Competitive Comparison of PharmaCielo's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCielo's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where PharmaCielo's Debt-to-Revenue falls into.

PharmaCielo Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

PharmaCielo's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.817	+	11.77)	/	5.309
	=	2.37

PharmaCielo's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.14	+	15.658)	/	1.408
	=	11.93

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2023) Revenue data.

PharmaCielo Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of PharmaCielo's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaCielo (TSXV:PCLO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PharmaCielo Ltd (TSXV:PCLO) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

PCLOF:USA

Address

82 Richmond Street East, Toronto, ON, CAN, M5C 1P1

Website

https://www.pharmacielo.com

PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico. It generates the majority of the revenue in the form of the Sale of Cannabis derivative products in Colombia.

Executives

Ian D Atacan

Director, Senior Officer

PharmaCielo (TSXV:PCLO) Headlines

No Headlines